We address some of the common questions we receive about inclusion and exclusion criteria for the FDA clinical trial of the 70cc TAH for Destination Therapy.
Learn what makes segmented polyurethane solution — the primary ingredient used to manufacture the SynCardia temporary Total Artificial Heart — so special.
For heart transplant recipients who experience graft failure, chronic allograft vasculopathy or rejection, the TAH overcomes limitations associated with the use of LVADs and BiVADs as a bridge to transplant in this population.
Right ventricular failure (RVF) is a serious and common complication in left ventricular assist device (LVAD) recipients that remains difficult to predict. A novel approach to patient consent may enhance your options in the operating room (OR) upon right ventricular (RV) visualization.